Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B

Liver Transplantation

Volumn 6, Issue 4, 2000, Pages 429-433

  Angus, Peter W ^a,b,c,d,e   McCaughan, Geoffrey W ^a,b,c,d,e   Gane, Edward J ^a,b,c,d,e   Crawford, Darryl H G ^a,b,c,d,e   Harley, Hugh ^a,b,c,d,e  

^a AUSTIN HOSPITAL   (Australia)

^b Australian National Liver Transplant Unit   (Australia)

^c Queensland Liver Transplant Service   (Australia)

^d South Australia Liver Transplant Unit   (Australia)

^e New Zealand Liver Transplant Unit   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH CARE COST; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MALE; NEW ZEALAND; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE;

EID: 0033944122     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2000.8310     Document Type: Article

References (20)

1. Liver transplantation for patients with hepatitis B: What have we learned from our results?
2. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
3. Hepatitis B virus re-infection after orthotopic liver transplantation. Serological and clinical implications
4. Liver transplantation in European patients with hepatitis B surface antigen
5. Liver transplantation for hepatitis B: The con aspect
6. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
7. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
8. High pretreatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
9. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
10. Hepatitis B virus precore mutant infection is associated with severe securrent disease after liver transplantation
11. Lamivudine therapy in patients transplanted for HBV precore mutant-associated infection; High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low-dose hepatitis B immune globulin
12. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunisation
13. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
14. Hepatitis B and C coinfections and persistent hepatitis B infections: Clinical outcome and liver pathology after transplantation
15. Long-term clinical and virologic outcome after liver transplantation for cirrhosis due to chronic delta hepatitis
16. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
17. Lamivudine as initial treatment for chronic hepatitis B in the United States
18. A one-year trial of lamivudine for chronic hepatitis B